Skip to main content
OpenTrials
Completed

NCT Number: NCT05706012

Antithrombotic Management of Acute Mesenteric Ischaemia

Guidelines on the acute and long-term pharmacological treatment of acute mesenteric ischaemia (AMI) recommend the use of thrombolytic, antiplatelet or anticoagulant therapy depending on the aetiology of AMI and the use of stenting but only few details are given on the choice of the drug, dose and duration of treatment. Besides, recommendations are mainly based on data on coronary, cerebral and other peripheral artery diseases and do also not take into account the altered drug absorption in patients with short bowel syndrome, in which AMI can result.This case-based survey will inform us on the current international clinical practice of long-term antithrombotic management of AMI.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Mesenteric Ischemia Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Malabsorption Syndromes Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Short Bowel Syndrome

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospitals Leuven

Leuven, 3000, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • gastro-enterologist or cardiologist with expertise in treating SBS patients resulting from AMI

Exclusion criteria

  • none

Treatment and study plan

Survey

Other

Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients

Primary outcomes

  1. Type of antithrombotic therapy

    Time frame: April 2023

    Overview of the type of long-term antithrombotic therapy that is prescribed in SBS patients with AMI, depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed

Secondary outcomes

  1. Duration of antithrombotic therapy

    Time frame: April 2023

    Overview of the duration of long-term antithrombotic therapy in SBS patients with AMI depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed.

  2. Initial dose of antithrombotic therapy

    Time frame: April 2023

    Overview of the initial dose of long-term antithrombotic therapy in SBS patients with AMI depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed.

  3. Dose adjustments of antithrombotic therapy

    Time frame: April 2023

    Overview of any dose adjustments of long-term antithrombotic therapy in SBS patients with AMI depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed.

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Registry information

Official study title

Long-term Antithrombotic Management of Acute Mesenteric Ischaemia: Case-based Survey

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jan 31, 2023
Registry last updated
May 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.